PT - JOURNAL ARTICLE AU - Kellie A. Schaefer AU - Wen-Hsuan Wu AU - Diana F. Colgan AU - Stephen H. Tsang AU - Alexander G. Bassuk AU - Vinit B. Mahajan TI - Response to Editas: Unexpected mutations after CRISPR-Cas9 editing <em>in vivo</em> AID - 10.1101/154450 DP - 2017 Jan 01 TA - bioRxiv PG - 154450 4099 - http://biorxiv.org/content/early/2017/06/23/154450.short 4100 - http://biorxiv.org/content/early/2017/06/23/154450.full AB - Here we provide additional confirmatory data and clarifying discussion, including sequencing data showing extensive heterozygous mutations throughout the genome in the CRISPR treated mice, which are all progeny of inbred mice purchased from a commercial vendor (JAX). The heterozygosity in these cases cannot be parentally inherited. The summary statements in our Correspondence reflect observations of a secondary outcome following successful achievement of the primary outcome using CRISPR to treat blindness in Pde6b/rd1 mice. As the scientific community considers the role of WGS in off-target analysis, future in vivo studies are needed where the design and primary outcome focuses on CRISPR off-targeting. We agree that a range of WGS controls are needed that include parents, different gRNAs, different versions of Cas9, and different in vivo protocols. We look forward to the publication of such studies. Combined, these results will be essential to fully understand off-targeting and can be used to create better algorithms for off-target prediction. Overall, we are optimistic that some form of CRISPR therapy will be successfully engineered to treat blindness.